performance of experiments were by AR, AM and JKV. This product
technology has been licensed by SignPath Pharma Inc. from UNTHSC.
APR and AM performed all optimization experiments, analyzed data and
wrote the manuscript. JKV supervised and mentored work and corrected the
manuscript. LH provided the funds in part for this research and reviewed the
manuscript. All authors read and approved the final manuscript.
This research was partially supported by SignPath Pharma Inc., Pennsylvania,
USA. Anindita Mukerjee was supported by Susan G. Komen postdoctoral
grant (KG101213). The authors would like to thank Sanjay Thamake for his
help in animal handling for the pharmacokinetics experiment. We would
also thank Laurie Mueller for processing the SEM samples at High Resolution
Scanning Electron Microscopy Facility at University of Texas Southwestern
Medical Center, Dallas, USA.
Department of Molecular Biology & Immunology and Institute for Cancer
Research, Graduate School of Biomedical Sciences, University of North Texas
Health Science Center, Fort Worth, TX76107, USA.
Inc., Quakertown, PA, USA.
Received: 10 May 2012 Accepted: 23 August 2012
Published: 31 August 2012
1. Bar-Sela G, Epelbaum R, Schaffer M: Curcumin as an anti-cancer agent:
review of the gap between basic and clinical applications. Curr Med
Chem 2010, 17:190–197.
2. Yallapu MM, Jaggi M, Chauhan SC: Curcumin nanoformulations: a future
nanomedicine for cancer. Drug Discov Today 2012, 17(1–2):71–80.
3. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR,
Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M,
Gescher AJ, Steward WP: Phase I clinical trial of oral curcumin: biomarkers
of systemic activity and compliance. Clin Cancer Res 2004,
4. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR,
Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS,
Pan MH, Wang YJ, Tsai CC, Hsieh CY: Phase I clinical trial of curcumin, a
chemopreventive agent, in patients with high-risk or pre-malignant
lesions. Anticancer Res 2001, 21(4B):2895–2900.
5. Liacini A, Sylvester J, Li WQ, Zafarullah M: Inhibition of interleukin-1-
stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor
kappa B (NF-kappa B) transcription factors down-regulates matrix
metalloproteinase gene expression in articular chondrocytes. Matrix Biol
6. Kurien BT, Scofield RH: Increasing aqueous solubility of curcumin for
improving bioavailability. Trends Pharmacol Sci 2009, 30(7):334–335.
7. Kurien BT, Scofield RH: Heat-Solubilized Curcumin Should Be Considered
in Clinical Trials for Increasing Bioavailability. Clin Cancer Res 2009,
8. Anand PP: Bioavailability of Curcumin: Problems and Promises. Mol
Pharm 2007, 4(6):807–818.
9. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR: Nanoparticle
encapsulation improves oral bioavailability of curcumin by at least 9-fold
when compared to curcumin administered with piperine as absorption
enhancer. Eur J Pharm Sci 2009, 37(3–4):223–230.
10. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A: Polymeric
nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy
for human cancer therapy. J Nanobiotechnol 2007, 5:3.
11. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK: Curcumin-
phospholipid complex: Preparation, therapeutic evaluation and
pharmacokinetic study in rats.
Int J Pharm 2007, 330(1–2):155–163.
12. Tiyaboonchai W, Tungpradit W, Plianbangchang P: Formulation and
characterization of curcuminoids loaded solid lipid nanoparticles. Int J
Pharm 2007, 337(1–2):299–306.
13. Yadav VR, Suresh S, Devi K, Yadav S: Novel formulation of solid lipid
microparticles of curcumin for anti-angiogenic and anti-inflammatory
activity for optimization of therapy of inflammatory bowel disease.
J Pharm Pharmacol 2009, 61(3):311–321.
14. Mukerjee A, Vishwanatha JK: Formulation, characterization and evaluation
of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res
15. Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, He J, Alb A,
John V, Pochampally R: Curcumin-loaded γ-cyclodextrin liposomal
nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine 2012,
16. Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC: Design of
curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug
Metab 2012, 13(1):120–128.
17. Chang L, Wu S, Tsai J, Yu T, Tsai T: Optimization of epirubicin
nanoparticles using experimental design for enhanced intravesical drug
delivery. Int J Pharm 2009, 376(1–2):195–203.
18. Murakami H, Kawashima Y, Niwa T, Hino T, Takeuchi H, Kobayashi M:
Influence of the degrees of hydrolyzation and polymerization of poly
(vinylalcohol) on the preparation and properties of poly(− lactide-co-
glycolide) nanoparticle. Int J Pharm 1997, 149(1):43–49.
19. LiL,ZhaoX,YangC,HuH,QiaoM,ChenD:Preparation and
optimization of doxorubicin-loaded albumin nanoparticles using
response surface methodology. Drug Dev Ind Pharm 2011, 37
20. Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, Peng X: Development and
optimization of solid lipid nanoparticle formulation for ophthalmic
delivery of chloramphenicol using a Box-Behnken design. Int J
2011, 6:683– 692.
21. Woitiski CB, Veiga F, Ribeiro A, Neufeld R: Design for optimization of
nanoparticles integrating biomaterials for orally dosed insulin. Eur J
Pharm Biopharm 2009, 73(1):25–33.
22. Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, Shi Y: Formulation
optimization of dihydroartemisinin nanostructured lipid carrier using
response surface methodology. Powder Technol 2010, 197(1–2):120–128.
23. Box GEP: Multi-factor experimental designs for exploring response
surfaces. Ann Mathematical Stat 1957, 28(1):195.
24. Derringer G, Suich R: Simultaneous optimization of several response
variables. J Qual Technol 1980, 12(4):214–219.
25. Ranjan AP, Zeglam K, Mukerjee A, Thamake S, Vishwanatha JK: A sustained
release formulation of chitosan modified PLCL:poloxamer blend
nanoparticles loaded with optical agent for animal imaging.
Nanotechnology 2011, 22(29):295104.
26. Karasulu E, Yesim Karasulu H, Ertan G, Kirilmaz L, Guneri T: Extended release
lipophilic indomethacin microspheres: formulation factors and
mathematical equations fitted drug release rates. Eur J Pharm Sci 2003,
27. Costa P, Sousa Lobo JM: Modeling and comparison of dissolution profiles.
Eur J Pharm Sci 2001, 13(2):123–133.
28. LiJ,JiangY,WenJ,FanG,WuY,ZhangC:A rapid and simple HPLC
method for the determination of curcumin in rat plasma: assay
development, validation and application to a p harmacokinetic
study of curcumin liposome. Biomed Chromatogr 2009,
29. Gonzalez-Mira E, Egea MA, Souto EB, Calpena AC, Garcia ML: Optimizing
flurbiprofen-loaded NLC by central composite factorial design for ocular
delivery. Nanotechnology 2011, 22(4):045101.
30. Duan Y, Xu S, Wang Q, Liu J, Zhang Z: Optimization of preparation of
DHAQ-loaded PEG-PLGA-PEG nonaparticles using central composite
design. J Mater Sci Mater Med 2006, 17(6):559–563.
31. Wu XG, Li G, Gao YL: Optimization of the preparation of nalmefene-
loaded sustained-release microspheres using central composite design.
Chem Pharm Bull 2006, 54:977.
32. Araujo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB: Optimization and
physicochemical characterization of a triamcinolone acetonide-loaded
NLC for ocular antiangiogenic applications. Int J Pharm 2010,
33. Kassama LS, Shi J, Mittal GS: Optimization of supercritical fluid extraction
of lycopene from tomato skin with central composite rotatable design
model. Sep Purif Technol 2008, 60(3):278–284.
34. Liu Y, Zhang P, Feng N, Zhang X, Wu S, Zhao J: Optimization and in situ
intestinal absorption of self-microemulsifying drug delivery system of
oridonin. Int J Pharm 2009, 365(1–2):136–142.
Ranjan et al. Journal of Nanobiotechnology 2012, 10:38 Page 17 of 18